



A 72-year-old man with diabetes was 
admitted in January 2017 with complaints of 
lower urinary tract symptoms and microscopic 
hematuria. Review of the medical history showed 
that in 2012 he had undergone transurethral 
resection of a low-grade pTa bladder tumor 
(TURBT), without signs of recurrence until February 
2017 when atypical urothelial cells were described 
by urine cytology and a small superfi cial bladder 
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neoplasm was found on cystoscopy. Hence, the 
patient was treated again with TURBT. At this 
time the pathological diagnosis was secondary 
carcinoma in situ (CIS) (Figures 1A-D), that was 
confi rmed by an additional pathologist review, so 
he was treated with 81mg of intravesical bacillus 
Calmette-Guerin (BCG) once weekly for 6 weeks+3 
weekly instillations every 3 months. Following 
the protocol of high-risk bladder cancer, upper 
urinary tract (UUT) was evaluated with computed 
tomography (CT) urography without signs of UUT 
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ABSTRACT
Bladder cancer is a common cancer that may present as superfi cial, invasive, or meta-
static disease. Non‐muscle‐invasive bladder cancer (NMIBC) represents the majority of 
bladder cancer diagnoses, but represents a spectrum of disease with a variable clinical 
course, notably for signifi cant risk of recurrence and potential for progression. NMIBC 
metastasis to distant organs without local invasion or regional metastasis is a very rare 
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disease (Figure 2). Thus, a second TUR (Re-TUR) 
with random bladder biopsies was performed 45 
days later, with non-tumoral bladder tissue in 
histopathology.
 Postoperatively, the patient was followed 
with cystoscopy and urinary cytology every three 
months and remained free of recurrence for 8 mon-
ths, when he complained about a left cervical mass. 
A cervical US (Figure 3A) and full-body CT scan 
(Figure 3B) revealed several left supraclavicular 
lymph node (LN) enlargement without evidence of 
local or regional (pelvic) recurrence. Fine-needle 
aspiration cytology (FNAC) of LNs was performed 
under US guidance. The immunochemical staining 
showed diffuse co-expression of cytokeratin 7 (Fi-
gure 1E), cytokeratin 20 (Figure 1F) and GATA-3 
(Figure 1G), with negative expression of TTF1 and 
napsin A, that definitely identified metastatic UC. 
He received 6 cycles of combination chemothera-
py (gemcitabine-cisplatin) every 4 weeks, with a 
Figure 1 - Histopathology of the bladder after TURBT: (A) H-E stain (20x) with high-grade urothelial CIS. (B) Strong full 
thickness expression of cytokeratin 20. (C) High proliferative activity measured by Ki67 index. (D) Strong and diffuse 
overexpression of p53 protein (positivity was seen throughout urothelial thickness). Immunochemistry after fine needle 
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Figure 2 - (A, B) Coronal and (C) axial scans of computed tomography (CT) urography without signs of UUT disease.
A B C
Figure 3 - (A) Ultrasound of the left supraclavicular region and (B) contrast-enhanced computed tomography scan showing 
enlarged left supraclavicular LNs (arrows).
A B
progressive clinical worsening, complicated by a 
fatal acute respiratory failure 5 months later.
DISCUSSION
 Bladder cancer (BC) is the seventh most 
commonly diagnosed cancer in the male popu-
lation worldwide (1). Approximately 75% of pa-
tients with BC present with a disease confined to 
the mucosa (Ta, CIS), or submucosa (T1), being the 
urothelial carcinoma (UC), the most frequent his-
tological subtype (2). NMIBC prognosis is based 
on the pathologic findings regarding tumor grade, 
multiplicity, size, concomitant CIS, depth of in-
vasion, and early recurrence, but are not adequa-
tely accurate in predicting the individual clinical 
behavior (3). TURBT is the initial critical step in 
the management and staging of disease. An ina-
dequate resection of the initial tumor (inadequate 
sampling of muscularis propria or missing tumors 
such as CIS) can lead to an improper staging and 
early recurrences (4). Half of all NMIBC patients 
will experience tumor recurrence within 5 years, 
and 20-30% will progress to secondary muscle-
-invasive bladder cancer (5). Ultimately, as many 
as 10-15% of patients presenting with NMIBC will 
die of bladder cancer (6), with progression-free 
5-year survival rate of 77% and an overall survi-
val rate of 63% after 5 years (7).
 CIS of the bladder is a flat, high-grade, 
non-invasive UC comprising about 10% of all ca-
ses of BC. The management of CIS continues to 
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present with many challenges, although intrave-
sical BCG has been accepted as first-line therapy, 
with overall response rate of 86.6% and a 5-year 
progression-free survival rate of 78.5% (8), this 
can be complicated by recurrence and progres-
sion. Recent study showed that 12% of CIS had a 
regional LN invasion after radical cystectomy (9), 
so EAU guidelines also recommend radical cystec-
tomy (10), mainly in patients with BCG refractory 
high risk NMIBC, rapid relapsing or refractory di-
sease (<6 months), T1 disease on repeat transure-
thral resection, high-volume multifocal high-gra-
de disease, presence of lymphovascular invasion 
with T1 disease, unfavorable or mixed histology, 
and poor patient compliance, because they are at 
significant risk of progression and metastasis (11, 
12). The current role of early cystectomy in CIS 
is controversial, some altered gene expression as 
high mRNA expression of ERBB2 is suggested to 
be useful to identify a high-risk group for progres-
sion who will benefit from an early cystectomy 
(13), although the potential for overtreatment 
must also be considered.
 This is a case of initially diagnosed NMIBC 
that developed early, multiple cervical metastases. 
It is very unusual for a patient with NMIBC to de-
velop head and neck metastasis without regional 
LNM or local invasion. It is difficult to establish 
the exact lymphatic pathways to the neck nodes 
from primary tumors arising below the clavicles, 
although there is a predilection for such metasta-
ses to be located to the left neck, while involve-
ment of right-sided neck nodes may be associa-
ted with more extensive mediastinal involvement. 
Rarely, cancers originating from sites other than 
head and neck can metastasize to the cervical LN 
chain. However, genitourinary tract tumors, make 
up a significant proportion of these cancers and 
should be considered in the differential diagnosis 
of metastatic lesions of the head and neck (14). 
CIS metastases to distant organs without local in-
vasion or regional metastases are a very rare oc-
currence, so there are limited case reports in the 
literature (3, 15, 16).
 Because of the low cost and high accu-
racy, the combination of US and FNAC represents 
a valuable and reliable method of choice for diag-
nosis in most cases of enlarged LNs from an unk-
nown primary (17). Immunohistochemical as well 
as molecular studies can render a more accurate 
tissue diagnosis and can be carried out on cyto-
logy samples, being GATA-3 the most helpful im-
mune stain for UC (17). Attempts to improve LN 
staging have shifted imaging towards increased 
use of MRI, which has a better soft tissue reso-
lution (being able to detect LNM in normal sized 
LNs) than conventional CT (18). Routine use of F-
-fluorodeoxyglucose (18F-FDG) positron emission 
tomography (PET)/CT is still not recommended in 
bladder cancer staging or in LNM detection (18), 
however, its use is becoming more common due 
to recent reports suggesting that PET/CT and SU-
Vmax interpretation is an appropriate tool in the 
evaluation of LN and can be used prior to surgery 
to make a safe identification of positive LNs (PET 
provides information on the potential malignancy 
of a LN through glucose metabolism by 18F-FDG 
uptake) (19).
 Metastatic BC remains an aggressive dise-
ase associated with limited treatment options and 
reduced survival. As many as 20% of patients will 
ultimately die of metastatic disease, and a signifi-
cant proportion will develop both intravesical and 
extravesical recurrences (4), being LNs, bones, and 
lung the three most common sites of metastasis.
 Standard treatment for metastatic cervical 
LN BC is not well established due to few cases re-
ported, however, palliative radiation therapy and 
chemotherapy has been offered (19). There is no 
current reported evidence to support therapeutic 
neck dissection for the management of BC metas-
tases to the neck (17,20).
 Some biomarkers, like p53 and Ki-67, 
are well studied and found to be correlated with 
progression in BC (21). Meanwhile, diabetic pa-
tients with NMIBC present more early distant 
metastases than expected, although they are 
non-invasive (22). For all this, high-risk patients 
with marked alterations in combined biomarker 
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